高危特殊人群的丙型肝炎微消除
世界卫生组织设定了2030年消除病毒性肝炎的目标,但多数国家目前偏离轨道。本文综述了将国家消除目标分解为关键人群微消除策略的进展与障碍,涵盖血液透析患者、注射吸毒者、囚犯、高流行区居民、男男性行为者、跨性别与性别多元人群及性工作者。扩大检测和治疗可及性以达成微消除,可能促进2030年全球丙肝消除。
要点
- 微消除将国家消除目标分解为可管理的关键人群目标,更具成本效益。
- 关键人群包括血透患者、注射吸毒者、囚犯、高流行区居民、MSM、跨性别与性别多元人群及性工作者。
- 扩大检测与治疗可及性以达成微消除,可能促进2030年全球丙肝消除。
核心结论
- 扩大检测和治疗可及性以达成HCV微消除,可能促进2030年全球HCV消除。
研究设计与样本
- 本文为综述,讨论特殊人群中HCV微消除的当前障碍与进展。
主要发现
- 大多数国家目前偏离2030年消除病毒性肝炎目标的轨道。
- 微消除将国家消除目标分解为更小、更可管理的关键人群目标。
- 关键人群具有HCV感染高流行和易感的共同特征。
- 微消除可更具成本效益和效率地识别HCV感染者并连接至照护。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization has set tremendous goals to eliminate viral hepatitis by 2030. However, most countries are currently off the track for achieving these goals. Microelimination is a more effective and practical approach that breaks down national elimination targets into goals for smaller and more manageable key populations. These key populations share the characteristics of being highly prevalent for and vulnerable to hepatitis C virus (HCV) infection. Microelimination allows for identifying HCV-infected people and linking them to care more cost-effectively and efficiently. In this review, we discuss the current obstacles to and progress in HCV microelimination in special populations, including uremic patients undergoing hemodialysis, people who inject drugs, incarcerated people, people living in hyperendemic areas, men who have sex with men with or without human immunodeficiency virus (HIV) infection, transgender and gender-diverse populations, and sex workers. Scaling up testing and treatment uptake to achieve HCV microelimination may facilitate global HCV elimination by 2030.
引用
- Huang CF, Chen GJ, Hung CC, et al. HCV Microelimination for High-risk Special Populations. J Infect Dis. 2023. PMID: 37703340. doi:10.1093/infdis/jiac446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。